• Triacetin Digestion and Absorption: New Rat Study

  2026-09-12

  A rat study shows that orally administered triacetin is rapidly degraded in the upper gastrointestinal tract and absorbed primarily as acetate and glycerol rather than reaching the colon intact. The findings identify triacetin as both a metabolic substrate and a potential regulator of hepatic AMPK-associated lipid metabolism, while also defining important limits for translation to human nutrition and disease research.

• Proteinase K for DNA Prep and Assay Controls

  2026-09-11

  Proteinase K combines broad protein digestion with compatibility across DNA isolation and protease-assay workflows. This guide shows how to use it for nuclease removal, high-quality genomic DNA preparation, and selectivity controls inspired by SARS-CoV-2 3CLpro inhibitor research.

• ARCA Cy5 EGFP mRNA (5-moUTP): A Benchmark

  2026-09-11

  A mechanistic and translational framework for using ARCA Cy5 EGFP mRNA (5-moUTP) to distinguish mRNA uptake, intracellular localization, release, and protein expression during delivery-system development.

• Eicosapentaenoic Acid (EPA) in Cell Assays

  2026-09-10

  Learn how Eicosapentaenoic Acid (EPA), SKU B3464, can be integrated into cell viability, migration, and cardiovascular research workflows with tighter control of concentration, vehicle, storage, and interpretation. This scenario-based guide distinguishes product-supported evidence from practical assay recommendations.

• IDH2, α-KG, and HIF-1α in Colorectal Cancer

  2026-09-10

  The reference study identifies mitochondrial IDH2 as a driver of colorectal cancer metabolic reprogramming, linking reductive citrate-cycle activity with α-ketoglutarate availability, HIF-1A stabilization, glycolysis, and tumor progression. Its combined genetic, pharmacological, cellular, and animal-model approach provides a framework for studying how mitochondrial metabolism and hypoxia signaling jointly sustain CRC growth.

• iTBS in SCA3 Mice: Motor and Molecular Effects

  2026-09-09

  A 2026 study in The Cerebellum shows that intermittent theta-burst stimulation (iTBS), but not continuous theta-burst stimulation (cTBS) to the same extent, improves coordination and modifies cerebellar pathology in SCA3/MJD mice. The work is notable for linking behavioral outcomes with ataxin-3 aggregation, neuroinflammatory markers, cytokine changes, and autophagy-related proteins.

• Deep Learning for iPSC-CM Cardiotoxicity Screening

  2026-09-09

  The eLife study developed a scalable workflow that combines high-content imaging, induced pluripotent stem cell-derived cardiomyocytes, and deep learning to detect cardiotoxic phenotypes across compound libraries. Its single-parameter scoring strategy supports early safety triage, while the reported limitations show why image-based predictions should be followed by mechanistic and electrophysiological validation.

• Nanoparticle PTEN mRNA Reverses Trastuzumab Resistance

  2026-09-08

  Dong and colleagues developed a tumor-microenvironment-responsive nanoparticle platform for systemic PTEN mRNA delivery in trastuzumab-resistant HER2-positive breast cancer models. By restoring PTEN expression and inhibiting PI3K/Akt signaling, the approach improved responsiveness to trastuzumab while illustrating how stimulus-responsive delivery can address resistance downstream of HER2.

• CD109, STAT3, and Chemoresistance in Colorectal Cancer

  2026-09-08

  A 2026 study identifies CD109 as a functional driver of colorectal cancer stemness, chemotherapy resistance, and metastatic colonization through an LRRC8A/AKAP12/PKCα–STAT3 signaling axis that sustains WNT activity. Its integrated patient-data, mechanistic, pharmacological, and mouse-model evidence positions CD109 as a candidate vulnerability in advanced colorectal cancer while clarifying important limits for translation.

• Arachidonic Acid and Vaccine-Induced Humoral Immunity

  2026-09-07

  The reference study identifies dietary arachidonic acid as a potential metabolic adjuvant that accelerates rabies vaccine-induced neutralizing antibody responses in mice and human volunteers. Its mechanistic analysis links lymph-node arachidonic acid metabolism to prostaglandin I2, cAMP–PKA signaling, CD86 expression, and activation-induced cytidine deaminase in B cells.

• Capsazepine: TRPV1 Antagonist for Better Pain Assays

  2026-09-07

  Capsazepine is a TRPV1 ion channel antagonist that helps dissect nociception, calcium signaling, and channel cross-reactivity. This guide translates recent multidimensional pain research into a practical assay strategy while defining the compound’s applications and limitations.

• Meropenem trihydrate: Assay Reliability Guide

  2026-09-05

  This scenario-based guide explains how Meropenem trihydrate, SKU B1217, can support bacterial infection, resistance, and cell-based assay workflows without confusing antibacterial effects with mammalian-cell toxicity. It combines product-handling data with recent LC-MS/MS evidence to improve experimental interpretation and reproducibility.

• Tyrothricin: Membrane Disruption Research Workflows

  2026-09-04

  Tyrothricin is a peptide antibiotic mixture suited to fast, orthogonal studies of bacterial and fungal membrane injury, with exploratory applications in infection-control models. This guide connects concentration-response testing, membrane-focused readouts, and the mitochondrial-transfer concepts highlighted in a recent orofacial inflammation study while keeping antimicrobial and mammalian-cell experiments analytically separate.

• AG-490 Workflows for JAK2/STAT6 Research

  2026-09-04

  AG-490, also called Tyrphostin B42, provides a practical pharmacological perturbation tool for connecting exosome-driven macrophage polarization with JAK-STAT and MAPK signaling. This workflow-focused guide shows how to test pathway dependence in hepatocellular carcinoma models while controlling for solubility, cytotoxicity, and multi-kinase selectivity.

• Dextromethorphan Hydrobromide in Cell Assays

  2026-09-03

  This scenario-based guide explains how Dextromethorphan hydrobromide, SKU B3478, can support controlled excitotoxicity, viability, and neuroprotection experiments. It connects mechanism, formulation, protocol design, interpretation, and vendor-selection decisions to improve assay reproducibility without overstating translational conclusions.

8066 records 1/538 page Next 12345 下5页 Last page